Tykerb Efficacy In Breast Cancer Not NICE Enough To Justify Price Tag, Says U.K. Agency
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis finds GSK's lapatinib and capecitabine combo therapy - at almost $50,000 annually - not cost-effective.